Leerink Partners upgrades enGene Therapeutics to Outperform from Market Perform, sets price target at $5
Leerink Partners upgraded enGene Therapeutics to Outperform from Market Perform, setting a $5 price target. This implies a 119.3% upside from the Nov 12 close of $2.28.

